Analysts think TNXP stock price could increase by 39%
Aug 06, 2025, 11:25 AM
-44.89%
What does TNXP do
Tonix Pharmaceuticals Holding, based in Chatham, New Jersey, specializes in developing therapeutics for CNS disorders and immunology, with a portfolio including TNX-102 SL for fibromyalgia and TNX-1500 for autoimmune diseases. Founded in 2010, the company employs 103 people and markets Zembrace SymTouch and Tosymra.
5 analysts think TNXP stock price will increase by 39.10%. The current median analyst target is $66.30 compared to a current stock price of $47.66. The lowest analysts target is $50.50 and the highest analyst target is $73.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
